Compare · BTTC vs GILD
BTTC vs GILD
Side-by-side comparison of Black Titan Corporation (BTTC) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BTTC and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $159.94B, about 93935.9x BTTC ($1.7M).
- Over the past year, BTTC is down 63.9% and GILD is up 23.4% - GILD leads by 87.3 points.
- GILD has been more active in the news (11 items in the past 4 weeks vs 8 for BTTC).
- GILD has more recent analyst coverage (25 ratings vs 0 for BTTC).
- Company
- Black Titan Corporation
- Gilead Sciences Inc.
- Price
- $1.39-6.08%
- $131.47+2.05%
- Market cap
- $1.7M
- $159.94B
- 1M return
- -9.74%
- -5.65%
- 1Y return
- -63.90%
- +23.39%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- News (4w)
- 8
- 11
- Recent ratings
- 0
- 25
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest BTTC
- Aterian, Inc. Announces Definitive Agreement for the Sale of its Marquee Brand Portfolio for $18 Million Subject to Adjustments
- SEC Form 6-K filed by Black Titan Corporation
- Institutional Digital Asset Infrastructure: The Maturation of Yield Routing and Restaking Rails
- SEC Form 6-K filed by Black Titan Corporation
- Crypto Payments Sector Advances as Managed Stablecoin Rails Launch, Merchant Use Cases Expand, and Regulatory Frameworks Tighten
- SEC Form 6-K filed by Black Titan Corporation
- The Institutional Stack Takes Shape: A Week of Stablecoin Infrastructure Buildout
- SEC Form 6-K filed by Black Titan Corporation
- Amendment: SEC Form F-1/A filed by Black Titan Corporation
- SEC Form 6-K filed by Black Titan Corporation
Latest GILD
- Chairman & CEO O'Day Daniel Patrick sold $1,291,608 worth of shares (10,000 units at $129.16) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 632,567 units (SEC Form 4)
- Gilead Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits, Other Events
- Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
- Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
- Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
- SEC Form 4 filed by Dickinson Andrew D
- SEC Form 4 filed by Mercier Johanna
- PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access
- Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE
- EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion